scPharmaceuticals (SCPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock and has a $25.00 price target.
Stacy Ku has given her Buy rating due to a combination of factors influencing scPharmaceuticals’ growth prospects. The launch of Furoscix has shown strong progress, with increasing patient demand and positive reception from key opinion leaders (KOLs) who appreciate its efficacy and ease of use. The drug’s expansion into Class IV heart failure and chronic kidney disease (CKD) labels is expected to further boost its adoption.
ScPharma’s financial performance reflects this momentum, with significant year-over-year and quarter-over-quarter growth in Furoscix sales. The company’s strategic focus on training and education for healthcare providers has resulted in a notable increase in prescribers, indicating a strong market acceptance. Additionally, the expansion of the sales force and planned launches are anticipated to sustain this growth trajectory. These factors collectively underpin Stacy Ku’s confidence in scPharmaceuticals’ potential, justifying the Buy rating.
According to TipRanks, Ku is an analyst with an average return of -8.2% and a 42.86% success rate. Ku covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, scPharmaceuticals, and VYNE Therapeutics.